Upload
Featured Recent Articles Topics Login Upload

Search Results for 'product biosimilar'

product biosimilar published presentations and documents on DocSlides.

Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by aaron
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by myesha-ticknor
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Biosimilar Biological Products
Biosimilar Biological Products
by luanne-stotts
2016 . Clinical Investigator . Training Course. S...
Comparison of US/EU Biosimilar
Comparison of US/EU Biosimilar
by danika-pritchard
Guidelines. Kamali Chance, MPH, PhD, RAC. Senior...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by stefany-barnette
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMIC Group Biosimilars 2014. Hyderabad India. 27-...
PhAMA Position on Biosimilar Medicines
PhAMA Position on Biosimilar Medicines
by celsa-spraggs
Ms. Leah Goodman. Contents. Key Messages. An Over...
Phil Johnson MS RPh Safe School Meds, Principle Partner
Phil Johnson MS RPh Safe School Meds, Principle Partner
by yoshiko-marsland
Moffitt Cancer Center, Director of Pharmacy (Reti...
Biosimilars in the united states – Update on FDA Impleme
Biosimilars in the united states – Update on FDA Impleme
by test
James C. Shehan. Hyman, Phelps & McNamara, P....
Phil Johnson MS
Phil Johnson MS
by stefany-barnette
RPh. Safe School Meds, Principle Partner. Moffitt...
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
Challenges in demonstrating biosimilarity and interchangeability of biosimilar products
by calandra-battersby
OMICS Group Biosimilars 2015 Birmingham, UK. 10-1...
Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives
Analytical Similarity Assessment: Practical Challenges and Statistical Perspectives
by alida-meadow
Richard Montes, Ph.D.. Hospira. , a Pfizer compan...
Biological Products: concepts, naming,
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
Faculty Leonard H. Calabrese, DO
Faculty Leonard H. Calabrese, DO
by trish-goza
Professor of Medicine. Cleveland Clinic Lerner Co...
22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum
22 MayEMACHMPBWP2477132012Committee for Medicinal Products for Hum
by carla
Adoption by CHMP for release for consultation24 Ma...
INSIGHTS INTO THE MARKET
INSIGHTS INTO THE MARKET
by summer
FOR INFLIXIMABTable of ContentsThe Evolving Landsc...
Category 1: Defining Terms
Category 1: Defining Terms
by jasmine
Clue: . A biologic product with no clinically mean...
US Regulatory Pathway For Biosimilars
US Regulatory Pathway For Biosimilars
by cheryl-pisano
Practical Legal/Regulatory Considerations Arising...
What You Need to Know About
What You Need to Know About
by marina-yarberry
Biosimilars. : Products, Recent Deals, IP Issues ...
Biosimilars
Biosimilars
by lindy-dunigan
Knowledge Connect Slide Resource. This slide dec...
JMP for Biosimilars : Tools for Analytical Similarity
JMP for Biosimilars : Tools for Analytical Similarity
by erica
Sept 16, 2015. W. Heath Rushing, . Adsurgo. LLC. ...
Concurrent Session 1B
Concurrent Session 1B
by yoshiko-marsland
View . from the Life Sciences . Industry. Moderat...
1 Immunogenicity The key safety issue for biosimilars
1 Immunogenicity The key safety issue for biosimilars
by gelbero
Prof. Ibrahim A. . Alsarra. Professor . of . Phar...
Medicare Part B Step Therapy Programs
Medicare Part B Step Therapy Programs
by elina
Page 1 of 10 UnitedHealthcare Medicare Advantag...
Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De
Nonproprietary Naming of Biological ProductsGuidance for IndustryUS De
by anastasia
x0000x0000 x/Attxachexd /xBottxom x/BBoxx 3x014x33...
Conference Series LLC
Conference Series LLC
by alida-meadow
Conferences. Conference Series LLC . is a pioneer...
Specialty Pharmacy and Biosimilars Created by the
Specialty Pharmacy and Biosimilars Created by the
by lois-ondreau
Specialty Pharmacy and Biosimilars Created by the ...
Biosimilars 2012 AIPLA Webinar
Biosimilars 2012 AIPLA Webinar
by stefany-barnette
September 25, 2012. 1. Denise. Kettelberger, PhD...
Biosimilars & EU regulation
Biosimilars & EU regulation
by karlyn-bohler
Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Defin...
ASBM Biosimilars US Prescribers and Biosimilars Naming
ASBM Biosimilars US Prescribers and Biosimilars Naming
by min-jolicoeur
Kevin Olson, CEO. Industry Standard Research. Kev...
PSHP President’s Update
PSHP President’s Update
by olivia-moreira
PSHP Annual Assembly. October 28, 2015. Matt Scol...
Latin American Physician Perspectives on Biosimilars
Latin American Physician Perspectives on Biosimilars
by celsa-spraggs
Presented at the . Latin American Biologics/Biosi...
Biosimilars in emerging markets- regulatory and Commercial considerations
Biosimilars in emerging markets- regulatory and Commercial considerations
by jane-oiler
OMIC Group. Biosimilars 2104. Hyderabad. India. 2...
PSHP President’s Update
PSHP President’s Update
by myesha-ticknor
PSHP Annual Assembly. October 28, 2015. Matt Scol...
NEUPOGEN filgrastim
NEUPOGEN filgrastim
by gelbero
GRANIX (tbo - filgrastim), NIVESTYM (filgrastim -...
Prescription Drug Resource Center
Prescription Drug Resource Center
by roberts
Generic Drug Substitution Laws May 3 , 2019 Compi...
Regulatory aspects and review
Regulatory aspects and review
by mary
of EMA authorized . biosimilars. Session “Biosim...